Cytek® Biosciences (CTKB) Announces $50 Million Stock Repurchase Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Cytek Biosciences Announces $50 Million Stock Repurchase Program
June 6, 2024 8:00 AM EDTFREMONT, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Companys common stock is listed on The Nasdaq Global Select Market under the symbol CTKB. The repurchase program will continue until December 31, 2024 unless extended or shortened by the Board of Directors.
Any repurchases would be made in the open... More
